About Gap junction beta-6 protein
Gap junction beta-6 protein (GJB6) is a protein
from Homo sapiens identified by UniProt accession
O95452, 261 residues long.
MolForge cross-references it against 0 known binders and
251 disease associations.
Target properties
| Protein name | Gap junction beta-6 protein |
|---|
| UniProt accession | O95452 |
|---|
| Gene | GJB6 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 261 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (251)
Diseases linked to this target (Open Targets).
- Clouston syndrome · score 0.82
- autosomal dominant nonsyndromic hearing loss · score 0.64
- autosomal recessive nonsyndromic hearing loss 1B · score 0.64
- autosomal dominant nonsyndromic hearing loss 3B · score 0.64
- hearing loss, autosomal recessive · score 0.63
- X-linked mixed deafness with perilymphatic gusher · score 0.46
- X-linked mixed hearing loss with perilymphatic gusher · score 0.45
- neurodegenerative disease · score 0.45
- KID syndrome · score 0.38
- Palmoplantar hyperkeratosis · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O95452-F1 | alphafold | PREDICTED | 82.21 | — |
Amino-acid sequence (261 residues)
MDWGTLHTFI GGVNKHSTSI GKVWITVIFI FRVMILVVAA QEVWGDEQED FVCNTLQPGC KNVCYDHFFP VSHIRLWALQ LIFVSTPALL VAMHVAYYRH ETTRKFRRGE KRNDFKDIED IKKQKVRIEG SLWWTYTSSI FFRIIFEAAF MYVFYFLYNG YHLPWVLKCG IDPCPNLVDC FISRPTEKTV FTIFMISASV ICMLLNVAEL CYLLLKVCFR RSKRAQTQKN HPNHALKESK QNEMNELISD SGQNAITGFP S
Explore Gap junction beta-6 protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets